|
COPYRIGHT 2005 International Medical News Group
Bevacizumab's success in improving lung, breast, and colorectal cancer survival has raised interest in other experimental antiangiogenic agents with the same target.
Notable among the trial results presented were updates on two such oral agents: PTK787/ZK 222584 (known as PTK/ZK) and AG-013736. Although they have different mechanisms, each is designed to prevent the vascular...
Read the full article for free courtesy of your local library.
| 
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
